CPX-351 induces remission in newly diagnosed pediatric secondary myeloid malignancies

Secondary myelodysplastic syndromes and acute myeloid leukemia (sMDS/AML) are rare in children and adolescents and have a dismal prognosis. The mainstay therapy is hematopoietic cell transplantation (HCT), but there has been no innovation in cytoreductive regimens. CP X-351, a fixed 5:1 molar ratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yixin, Caldwell, Kenneth J., Onciu, Mihaela, Federico, Sara M., Salek, Marta, Lewis, Sara, Lei, Shaohua, Zhang, Jinghui, Nichols, Kim E., Takemoto, Clifford M., Triplett, Brandon M., Farrar, Jason E., Rubnitz, Jeffrey E., Ribeiro, Raul C., Wlodarski, Marcin W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2022
Materias:
Stimulus Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791570/
https://www.ncbi.nlm.nih.gov/pubmed/34710216
http://dx.doi.org/10.1182/bloodadvances.2021006139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791570/
https://www.ncbi.nlm.nih.gov/pubmed/34710216
http://dx.doi.org/10.1182/bloodadvances.2021006139

Ejemplares similares